Circular Genomics
Personalized Diagnostics for Neurological Disorders
An industry first, Circular Genomics is developing a platform leveraging a novel and stable form of RNA, known as circular RNAs, as biomarkers to help patients suffering from psychiatric and neurological disorders find the most effective personalized treatment. The company’s first product aims to predict a patient’s sensitivity to anti-depressants before treatment, allowing clinicians to make better choices and provide faster, more effective relief for patients.
Latest Circular Genomics News
Circular Genomics Strengthens Scientific Advisory Board with the Addition of Esteemed Alzheimer’s Experts
Michael Weiner, MD and Timothy Hohman, PhD, bring decades of experience in neurological diseases with a focus on Alzheimer’s disease SAN DIEGO, Dec. 8, 2025 /PRNewswire/ — Circular Genomics, a…
-
Circular Genomics Announces Closure of $15 Million Series A Financing to Advance First-in-Class Circular RNA Platform for Early Detection of Alzheimer’s Disease
SAN DIEGO, Dec. 1, 2025 /PRNewswire/ — Circular Genomics, Inc., the world-leading developer of circular RNA-based precision medicine tools for neurology and psychiatry, today announced the successful closure of a $15…
-
Circular Genomics to Unveil New Data Highlighting Circular RNAs as a Transformative New Class of Blood-Based Biomarkers for Alzheimer’s Disease at CTAD 2025
New clinical data highlights circular RNAs (circRNAs) as a novel, non-invasive blood biomarker platform for the early detection of Alzheimer’s Disease (AD). The research demonstrates that circRNAs offer comprehensive insights into…
Circular Genomics Receives $250K Investment from the Alzheimer’s Drug Discovery Foundation (ADDF) to Advance First-in-Class Circular RNA Blood-Based Biomarker Tests for the Early Detection of Alzheimer’s Disease
SAN DIEGO, July 8, 2025 /PRNewswire/ — Circular Genomics, Inc., a global leader in circular RNA (circRNA) biomarkers for precision neurology and psychiatry, today announced it has received a $250,000…
-
Circular Genomics Joins Lilly Gateway Labs in San Diego to Develop Its Best-In-Class Circular RNA Platform for the Diagnosis and Prognosis of Alzheimer’s Disease
SAN DIEGO, March 17, 2025 /PRNewswire/ — Circular Genomics, a global leader in circular RNA (circRNA) biomarkers for precision neurology and psychiatry, today announced it is moving the company’s headquarters…
Circular Genomics Announces Launch of MindLight™, the First SSRI Antidepressant Response Test Using Brain-Derived Biomarkers
ALBUQUERQUE, N.M., Sept. 16, 2024 /PRNewswire/ — Circular Genomics, the global leader in circular RNA biomarkers for precision psychiatry and neurology, today announced the launch of MindLight, the first circular…
-
Circular Genomics Adds Dr. Michael Ackermann, PhD, MBA to its Scientific Advisory Board
ALBUQUERQUE, N.M., March 18, 2024 /PRNewswire/ — Circular Genomics, the global leader in circular RNA biomarkers for precision psychiatry and neurology, today announced the addition of Michael F. Ackermann, PhD,…
-
Circular Genomics Strengthens Leadership Team with Key Commercial and Research Hires
ALBUQUERQUE, N.M., Feb. 26, 2024 /PRNewswire/ — Circular Genomics, the global leader in advancing circular RNA biomarkers for precision psychiatry and neurology, today announced the appointments of Dave Karlander as…
-
Circular Genomics Raises $8.3 Million for Debut of Circular RNA Assay in Precision Psychiatry
ALBUQUERQUE, N.M., Jan. 24, 2024 /PRNewswire/ — Circular Genomics, the global leader in advancing circular RNA biomarkers for precision psychiatry and neurology, today announced the closing of an $8.3 Million Series…
-
Circular Genomics Announces Two Significant Steps Forward in Linking CircRNA to the Detection, Therapy Selection and Monitoring of Depressive Conditions
Albuquerque, NM, July 11, 2023 (GLOBE NEWSWIRE) — Circular Genomics, the global leader in the use of circular RNA (circRNA) biomarkers for precision psychiatry, today announced the results of a…